The PREVENT program supports the preclinical development of innovative cancer prevention interventions and biomarkers toward clinical applications. PREVENT uses NCI contract resources and expertise, instead of direct funding, to generate data and materials needed for agent development. The program is a peer-reviewed pipeline focused on unmet research needs that are not adequately addressed by the private sector. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.
Read more About PREVENT.
Submission deadlines occur twice per year on the first Monday in February and September.
NEXT Deadline: February 3, 2020
95 Projects from PREVENT Cycles 1 through 16:
- 59 chemoprevention projects
- 28 immunoprevention projects
- 8 biomarker projects
Read more about supported projects and supported prevention approaches.
- Efficacy and Intermediate Endpoint Biomarker Work
- Toxicology and Pharmacology Testing
- CGMP Production of Vaccines and Biologicals
- Prime Contractors 2019–2023
- Governance Structure
- Intellectual Property Considerations
- Data Access
PREVENT and Consortia Project Results Presented at the AACR Annual Meeting 2019
NCI participated in the American Association for Cancer Research (AACR) Annual Meeting held March 29 - April 3, 2019 at Georgia World Congress Center in Atlanta, GA, including the presentation of research results from the latest PREVENT- and Consortia-supported projects.